89bio Announces Additional Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Amid Share Price Decline
In a recent press release, 89bio, Inc.(Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic diseases, announced the approval of non-qualified stock options for new employees as part of their Inducement Grants program.This marks the third time this year that the Compensation Committee of the Company’s Board of Directors has approved such grants.
On May 6, 2024, 48,150 shares of the Company’s common stock were granted to four new employees, following previous grants of 138,550 shares to eight employees in April and 28,400 shares to two employees in February.These Inducement Grants were made under the Company’s 2023 Inducement Plan as an incentive for individuals to join 89bio’s workforce.
Despite the positive news of attracting new talent, 89bio Inc.’s share price has experienced a decline in May 2024, standing at $9.11.During this month, ETNB shares dropped by 5.37%. This fluctuation in the stock market may raise questions about the company’s performance and future outlook.
The series of Inducement Grants made by 89bio underscores their commitment to attracting top talent in the biopharmaceutical industry.However, investors will be keeping a close eye on how this influx of new employees will impact the company’s growth trajectory in the coming months.
Comments